Voyager’s AADC Gene Therapy Shows Promise as Maintenance Therapy for Parkinson’s
Voyager Therapeutics’ new clinical data on VY-AADC01 as a maintenance therapy for advanced Parkinson’s disease shows improvement in patients’ motor function after just one dose, and with meaningfully lower doses of oral levodopa. The company presented ongoing Phase 1b trial (NCT01973543) results at the Oct. 17-20 Congress of the European Society…